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Abstract. Cytochrome P450 2E1 (CYP2E1) is one of the main 
enzymes involved in the oxidation of ethanol and in the trans-
formation of a number of potentially dangerous compounds. It 
has various polymorphic sites, one of which is a variable number 
tandem repeat (VNTR) polymorphism previously described in 
the 5'-flanking region. The aim of this study was to investigate 
the genotype-phenotype association between CYP2E1 VNTR 
polymorphisms and risky health habits in healthy subjects 
and to analyze the associations between these polymorphisms 
with drinking- and/or smoking-related cancers. We analyzed 
166 healthy subjects by genotyping for the CYP2E1 VNTR 
polymorphism associated with drinking and/or smoking 
habits by the more sensitive restriction fragment length poly-
morphism-polymerase chain reaction (RFLP-PCR) method, 
using the NlaIV restriction enzyme. Sixty cases of pancreatic 
adenocarcinoma (PA) and 66 with hepatocellular carcinoma 
(HCC), were also genotyped. Statistical analysis was carried 
out to investigate the genotype-phenotype associations and to 
compare certain genotypes and cancer. We found 7 genotypes 
both in the healthy subjects and patients. The A1/A1 genotype 
was observed to be mainly associated with non-drinkers and 
-smokers (87.5 and 75.0%, respectively); moreover it was 
never found in the PA or HCC patients. Conversely, a weak 
association between A2/A3 with smokers (45.8%) and A4/A4 
with drinkers (53.9%) was detected. In addition, the A4/A4 
genotype was found to be significantly associated to PA [odds 
ratio (OR)=3.25; 95% confidence interval (CI) 1.21-7.50]. Our 
data demonstrate that certain CYP2E1 VNTR genotypes are 
associated with drinking and/or smoking habits; consequently, 
they may contribute either to the decreased or increased risk 
of developing drinking- and/or smoking-related cancers. In 
particular, we hypothesize that the A1/A1 VNTR genotype 
may have a protective role against drinking- and/or smoking-
related cancers, and that A4/A4 may be a high-risk genotype 
during the early stages of cancer.
Introduction
During the last few years, it has been documented that alco-
holism is increasing among young persons (1). Alcohol is 
metabolized by the liver cells (hepatocytes) via 3 pathways: 
the alcohol dehydrogenase pathway in the cytosol, the micro-
somal ethanol oxidizing system in the endoplasmic reticulum 
and catalase in the peroxisomes. All 3 pathways result in the 
production of acetaldehyde, which is then metabolized by 
aldehyde dehydrogenase (ALDH) into acetate, a metabolite 
more toxic than alcohol itself (2-4).
Cytochrome P450 2E1 (CYP2E1) is the main enzyme in the 
microsomal ethanol oxidation system (5), and it is a member of 
the cytochrome P450 (CYP) superfamily, a membrane-bound 
protein primarily associated with endoplasmic reticulum 
membranes. CYP2E1 has also been shown to be involved in 
the metabolism of more than 80 low-molecular hydrophobic 
toxicologically dangerous compounds and contributes to the 
activation of a number of pro-carcinogens and drugs into highly 
reactive metabolites (6,7). Specifically, CYP2E1 activates 
N-nitrosamines contained in tobacco smoke and foodstuffs 
(8-10) and several industrial (11) and endogenous carcinogens 
(12,13); moreover, it is capable of reducing mole cular oxygen to 
highly reactive compounds, such as superoxide anion radical 
(О2
-), singlet oxygen (1О2), hydrogen peroxide (H2O2) and 
hydroxyl radical (ОН·) leading to DNA damage and carcino-
genesis (14,15).
The human CYP2E1 gene is located on chromosome 
10q26.3 and consists of 9 exons and 8 introns. CYP2E1 gene 
expression may be regulated at the transcription and translation 
level, as well as the mRNA stabilization and protein degrada-
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tion levels (16,17). Similar to other CYP genes, CYP2E1 has 
more than 10 different polymorphic sites, in the 5'-flanking 
region, in introns and transcribed gene regions. In particular, a 
polymorphic variable number tandem repeat (VNTR) sequence 
has been described ~2.0 kb pair upstream of the transcription 
start site (18).
There is a high variability among different ethnic groups 
in the activity of the CYP enzyme due to both environmental 
and genetic factors, such as polymorphisms. Polymorphic 
CYP genes are capable of creating differences in the ability 
to metabolize, detoxify or activate a number of substances. 
This ability, as is well known, provides one of the first lines 
of defence against xenobiotic chemicals; therefore, we hypthe-
sized that an alteration in the activity of these enzymes may 
result in a greater susceptibility to certain diseases or cancer, 
although existing evidence on the matter is controversial (19). 
A number of studies have clarified that certain polymorphic 
genes, in association with alcohol consumption, are involved 
in the development of certain cancers (20-22). Despite the fact 
that alcohol is not itself a carcinogen, it acts as a co-carcinogen 
by enhancing the effects of other chemicals activated by 
certain enzymes, i.e. CYP2E1. Certain studies have demon-
strated that CYP2E1 is highly expressed in both the liver 
and pancreas after ethanol administration (23). Acetaldehyde 
produced during ethanol oxidation may be the direct cause 
of cell damage via the production of reactive oxygen species 
(ROS). Moreover, it is currently well known that certain 
tumours are heritable (24,25) and that environmental hazards 
associated with particular habits may increase the risk of 
tumour insurgence. In this study, we investigated CYP2E1 
VNTR polymorphism distribution among healthy subjects by 
analyzing whether particular CYP2E1 VNTR polymorphisms 
were associated with certain health-risk behaviours, such as 
alcohol consumption and/or cigarette smoking. Finally we 
analyzed patients with pancreatic adenocarcinoma (PA) and 
hepatocellular carcinoma (HCC) in order to find evidence of 
a possible correlation between certain CYP2E1 VNTR poly-
morphisms, risky habits and predisposition to cancer.
Subjects and methods
Healthy subjects and patients. In this study, 166 apparently 
healthy subjects (106 females and 60 males, aged 19 to 34 years, 
residents of sourthern Italy) were enrolled. All the patients and 
subjects gave their written informed consent to participate 
in the study. A questionnaire to determine their age, as well 
as their drinking and smoking habits was compiled by each 
person. Accordingly, the subjects were considered as drinkers 
if they drank approximately 1 glass/day and as smokers if 
they smoked between 1-5 cigarettes/day. Moreover, to better 
understand the possible association between CYP2E1 VNTR 
genotypes and drinking- and/or smoking-related neoplastic 
diseases, we genotyped 60 cases of PA and 66 with HCC, 
collected from the same geographical area.
DNA extraction. Genomic DNA was obtained from the saliva 
of healthy subjects and from the peripheral blood lymphocytes 
of patients. DNA was purified using a PureLink™ Genomic 
DNA mini kit according to the manufacturer's instructions 
(Invitrogen).
Genotyping. To genotype the CYP2E1 VNTR polymorphism, 
we performed restriction fragment length polymorphism-
polymerase chain reaction (RFLP-PCR) using a final volume 
of 50 µl containing 150 ng of genomic DNA, 0.2 mM of 
each dNTP, 1.5 mM of MgCl2, 0.05 U/µl of Taq polymerase 
(Invitrogen) and 0.4 µM of each primer: 5'-CAC ACC CAG 
CCA ACA GCA G-3' (sense) and 5'-TGC ATC TGT CCC ATT 
GGC AG-3' (antisense) (16). PCR was carried out by 30 thermal 
cycles under the following conditions: 4 min at 94˚C for initial 
melting, 1 min at 94˚C for melting, 1 min at 58˚C for primer 
annealing and 1 min at 72˚C for primer extension.
Half of the PCR product was subjected to restriction endo-
nuclease digestion by NlaIV (0.5 U/µl, BioLabs) at 37˚C for 
2 h. Digested and non-digested samples were analyzed by a 
12% polycrylamide gel stained with SYBR Safe DNA gel stain 
(Invitrogen) and visualized by ChemiDoc XRS (Bio-Rad).
Statistical analysis. Statgraphics data analysis (plus version 
5.1) was used to investigate the associations between geno-
types and drinking and/or smoking. In order to evaluate the 
heredity equilibrium, we used the Hardy-Weinberg test. The 
association of the genotypes with the risk of PA or HCC was 
investigated by evaluating the odds ratio (OR) and 95% confi-
dence interval (CI) using SPSS software.
Results
Phenotype distribution. Table I shows some information 
obtained from the phenotype study carried out on healthy 
subjects. As can be observed, the population consisted of 63.9% 
females and 36.1% males. No significant difference between 
the genders was observed regarding the mean age (21.8±3.0 vs. 
21.3±2.4 years, for males and females, respectively).
Genotype distribution. Table II shows the CYP2E1 VNTR 
genotype frequencies detected in the healthy subjects. We 
found 7 VNTR-CYP2E1 genotypes: A1/A1, A1/A2, A2/A2, 
A2/A3, A2/A4, A3/A3 and A4/A4. The most frequent geno-
type was A2/A2 (63.8%), and A1/A2 and A3/A3 were the least 




  Male    60 (36.1)
  Female 106 (63.9)
Age (mean ± SD) 21.2±2.2
  Male 21.8±3.0
  Female 21.3±2.4
Drinking habit
  Never  117 (70.5)
  Ever    49 (29.5)
Smoking habit
  Never 113 (68.1)
  Ever    53 (31.9)
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frequent (0.6%), whereas genotypes A1/A3, A1/A4 and A3/A4 
were not detected. All the genotypes detected in this study 
were in Hardy Weinberg equilibrium.
Genotype association with habitual drinking. In order 
to investigate whether particular CYP2E1 VNTR poly-
morphisms are associated with alcohol consumption, we 
differentiated the frequencies of non-drinkers or drinkers 
within each genotype; the results are reported in Table III. 
As can be observed, the A4/A4 genotype increased the OR 
for drinking habit (3.08; 95% CI 0.97-9.70) while the A1/
A1 genotype was not associated with any increased OR for 
drinking habit.
Genotype association with habitual smoking. In order to 
investigate whether particular CYP2E1 VNTR polymorphisms 
are associated with habitual smoking, we differentiated the 
frequencies of non-smokers or smokers within each genotype; 
the results are reported in Table IV. The A2/A3 genotype for 
smoking habit increased the OR (2.73; 95% CI 1.15-6.50) and 
intere stingly, the A1/A1 genotype was not associated with any 
increased OR for this risky habit.
Genotype association with healthy subjects and cancer cases. 
The results presented in Table V show the distribution of 
CYP2E1 genotypes in healthy subjects, PA and HCC patients.
It is worth noting that no cases, neither PA nor HCC with the 
A1/A1 genotype were found. Moreover a significant differ-
ence was found in the correlation with PA; in fact there was 
a greater percentage of PA cases with the A4/A4 genotype 
(OR=3.25; 95% CI 1.41-7.50). No significant differences were 
detected in the HCC cases.
Table II. CYP2E1 VNTR genotype distribution in healthy subjects.
 CYP2E1 VNTR genotype, no. (%)
 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Total
 A1/A1 A1/A2 A1/A3 A1/A4 A2/A2 A2/A3 A2/A4 A3/A3 A3/A4 A4/A4 no. (%)
Healthy 16 (9.6) 1 (0.6) 0 0 106 (63.8) 24 (14.5) 5 (3.0) 1 (0.6) 0 13 (7.8) 166 (100)
subjects
CYP2E1, cytochrome P450 2E1; VNTR, variable number tandem repeat.
Table III. Distribution of CYP2E1 genotypes according to alcohol consumption in healthy subjects.
 CYP2E1 VNTR genotype, no. (%)
Healthy --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Total
subjects A1/A1 A1/A2 A1/A3 A1/A4 A2/A2 A2/A3 A2/A4 A3/A3 A3/A4 A4/A4 no. (%)
Non-drinkers 14 (87.5)  1 (100) 0 0 73 (68.9) 18 (75.0) 4 (80.0) 1 (100) 0 6 (46.1) 117 (70.5)
Drinkers   2 (12.5) 0 0 0 33 (31.1)   6 (25.0) 1 (20.0) 0 0 7 (53.9)   49 (29.5)
  ORa 0.31 1.00   1.36 0.76 0.58 1.00  3.08
  95% CI 0.06-1.43 0.99-1.02   0.66-2.78 0.28-2.06 0.06-5.40 0.99-1.02  0.97-9.70
CYP2E1, cytochrome P450 2E1; VNTR, variable number tandem repeat. aOR, odds ratio (calculated vs. non-drinkers); CI, confidence interval.
Table IV. Distribution of CYP2E1 genotypes according to smoking habit in healthy subjects.
 CYP2E1 VNTR genotype, no. (%)
Healthy --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Total
subjects A1/A1 A1/A2 A1/A3 A1/A4 A2/A2 A2/A3 A2/A4 A3/A3 A3/A4 A4/A4 no. (%)
Non-smokers 12 (75.0) 1 (100) 0 0 73 (69.8) 12 (50.0) 5 (100) 1 (100) 0 9 (69.2) 113 (68.1)
Smokers   4 (25.0) 0 0 0 33 (30.2) 12 (50.0) 0 0 0 4 (30.8) 53 (31.9)
  ORa 0.68 1.00   1.06 2.73 1.04 1.00  0.94
  95% CI 0.21-2.24 0.99-1.02   0.53-2.11 1.15-6.50 1.00-1.08 0.99-1.02  0.27-3.21
CYP2E1, cytochrome P450 2E1; VNTR, variable number tandem repeat. aOR, odds ratio (calculated vs. non-smokers); CI, confidence interval.
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Discussion
It is known that alcohol consumption and cigarette smoking are, 
unfortunately, increasing among young persons (1). Moreover, 
it is well known that these dangerous injuries exert an influ-
ence on susceptibility to tumours, such as PA (26) and HCC. 
These social and clinical problems drove us to explore whether 
an association exists between particular genetic factors, 
health-risk behaviours, as well as drinking- and/or smoking-
related neoplastic diseases. We focused our attention on CYP 
genes and in particular, on CYP2E1, which is a polymorphic 
gene involved not only in the ethanol oxidative metabolism, 
but also in the transformation of many exogenous compounds, 
including N-nitrosamines, which may be activated into highly 
reactive metabolites. Polymorphisms in this gene can create 
differences in the ability to metabolize, detoxify or activate a 
number of substances. This ability can generate certain reac-
tive substances which may consequently increase the risk of 
deve loping serious diseases, such as tumours (7,8,14,27).
The VNTR polymorphism in the 5'-flanking region of the 
CYP2E1 gene has previously been described (18). Moreover, 
to date, only a few studies have focused on this polymorphism 
and its asociation with drinking and/or smoking and cancer 
development (16). We formed the hypothesis that the VNTR 
polymorphism may be responsible (together with others) for the 
different susceptibility to serious diseases which are caused, 
directly or indirectly, by drinking and/or smoking. In this study, 
we report for the first time, the results of VNTR CYP2E1 
genotyping, carried out in 166 young healthy individuals and 
126 patients (60 PA and 66 HCC), residents of southern Italy.
In order to genotype the VNTR polymorphisms, we devel-
oped a simple and precise technique in our laboratory, suitable 
as a hospital diagnostic routine, consisting of PCR followed by 
enzyme digestion to improve sensitivity and resolution.
We found 7 out of 10 expected genotypes: A2/A2 was the 
most frequent and A1/A2, A3/A3 were the least frequent both 
in the healthy subjects and patients. The genotypes, A1/A3, 
A1/A4 and A3/A4, were not detected. As A2/A2 was the modal 
genotype in all the studied subjects, we believe that this allele 
provides a generic selective advantage in humans.
We considered the results regarding the other no-modal 
genotypes more interesting. In fact, in all the association 
analyses between the health-risk behaviours and VNTR geno-
types, we found that individuals with the A1/A1 genotype had a 
lower inclination either to drink or smoke (the lowest OR values 
shown in Tables III and IV), whereas individuals with the A4/A4 
genotype had an inclination to drink and those with the A2/A3 
genotype a propensity to smoke. Consequently, individuals 
with the A1/A1 genotype are exposed neither to potentially 
dangerous molecules inhaled by smoking and transformed by 
the CYP2E1 enzymes, nor to the ROS produced by the CYP 
over-activity induced by alcohol ingestion. This genotype may 
determine a lower susceptibility to drinking- and/or smoking-
related neoplastic diseases, hence it may be considered a 
protective genetic order. Otherwise, A4/A4 subjects are exposed 
to the continual alcohol induction of the CYP2E1 gene; there-
fore, they are promptly able to transfrom certain incidentally 
absorbed pro-carcinogens into active toxic molecules and to 
increase CYP activity-derived ROS production. This genotype, 
therefore, may be associated with the susceptibility to develop 
serious drinking-related diseases.
These results led us to investigate whether an associa-
tion between the A4/A4 genotype and tumour susceptibility 
exists; therefore, we genotyped patients with drinking- and/or 
smoking-related tumours (i.e. PA and HCC). In confirmation 
of the results obtained from the healthy subjects, the A1/A1 
genotype was found neither among PA nor HCC patients and 
A4/A4 PA cases were significant (~3-fold) with respect to the 
controls (OR=3.25; 95% CI 1.21-7.50) (Table V).
Nowadays, little is known about the risk factors for pancre-
atic cancer (20) and in particular, there are controversial data 
about alcohol consumption (28) as a susceptibility factor. Our 
results show that one of the VNTR CYP2E1 genotypes could 
be a susceptibility factor for PA, either directly, by conferring 
a higher expression of the CYP2E1 gene, or indirectly, by 
being associated with drinking habits. It has previously been 
reported that transcriptional activity is increased in subjects 
with the A4 allele (16) and the inductive effect of ethanol on 
CYP2E1 gene expression (12) and on ROS production is well 
known (29).
Table V. Distribution of CYP2E1 genotypes in healthy subjects, PA and HCC patients.
 CYP2E1 VNTR genotype, no. (%)
 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Total
 A1/A1 A1/A2 A1/A3 A1/A4 A2/A2 A2/A3 A2/A4 A3/A3 A3/A4 A4/A4 no. (%)
Control 16 (9.64) 1 (0.60) 0 0 106 (63.86) 24 (14.46) 5 (3.01) 1 (0.60) 0 13 (7.83)  166 (100)
PA 0 0  0 0   38 (63.33) 4 (6.67) 5 (8.33) 0  0 13 (21.67)   60 (100)
  ORa 1.10 1.00   0.97 0.42 2.97 1.00  3.25
  95% CI 1.05-1.16 0.99-1.01   0.53-1.80 0.14-1.27 0.81-10.49 0.99-1.01  1.41-7.50
HCC 0 2 (3.03)  0 0   52 (78.79) 11 (16.67) 0  0  0 1 (1.51)   66 (100)
  ORa 1.10 5.15   2.12 1.18 1.03 1.00  0.18
  95% CI 1.05-1.16 0.46-57.8   1.07-4.10 0.54-2.57 1.00-1.05 0.99-1.01  0.02-1.41
CYP2E1, cytochrome P450 2E1; VNTR, variable number tandem repeat. PA, pancreatic adenocarcinoma; HCC, hepatocellular carcinoma; 
aOR, odds ratio (calculated vs. control); CI, confidence interval.
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We hypothesized that the A4/A4 genotype, having a double 
dose of the A4 allele, may be associated with a greater suscep-
tibility to PA, confirming the suspicions reported previously 
regarding other cancers (16), especially for subjects which 
have an inclination to alcohol consumption.
We consider that further studies are required to further 
confirm this hypothesis. In parti cular, it may be of interest to 
study the real contribution of VNTR alleles in CYP2E1 gene 
expression, as well as their regulatory elements contained in the 
5'-flanking region, either genetic, or epigenetic.
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